Evaluation of efficacy and safety of montelukast and levocetirizine FDC tablet compared to montelukast and levocetirizine tablet in patients with seasonal allergic rhinitis: a randomized, double blind, multicentre, phase III trial


  • Sagar Panchal Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, Maharashtra, India
  • Saiprasad Patil Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, Maharashtra, India
  • Hanmant Barkate Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, Maharashtra, India




Allergy, Histamine, Leukotriene, LTRA, SGAH


Background: To evaluate efficacy, safety and tolerability of Montelukast 10 mg+levocetirizine 5 mg  FDC compared to either montelukast 10 mg or levocetirizine 5 mg given alone in seasonal allergic rhinitis (SAR) patients.

Methods: Phase III, multicentre, randomized, double blind, parallel group, active controlled study was conducted in 279 SAR patients at 16 sites across India. Efficacy was assessed using daytime nasal symptoms score (Primary efficacy outcome), night-time symptoms score, daytime eye symptom score, patient's global evaluation, physician's global evaluation, rhino-conjunctivitis quality-of-life score.  

Results: At end of treatment there was statistically significant evidence from the per protocol analysis that patients on FDC had a greater improvement in change from baseline in daytime nasal symptoms score than patients who received Montelukast (p=0.0266) or Levocetirizine (p=0.0409). These results were consistent with the Intent to treat analysis. Analysis of the secondary efficacy endpoints provided numerically greater improvement in the nighttime symptoms score, daytime eye symptoms score, and rhinoconjunctivitis quality-of-life scores in the FDC group as compared to the Montelukast group or Levocetirizine group. The FDC of Montelukast and Levocetirizine was found to be safe and generally well tolerated. The majority of adverse events were mild in severity, resolved without treatment and were unrelated to study medication.

Conclusions: Fixed dose combination of Montelukast and Levocetirizine was safe, generally well tolerated and superior on efficacy compared to Montelukast or Levocetirizine in patients of seasonal allergic rhinitis.


Wallace DV, Dykewicz MS, Bernstein DI. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:1-84.

Storms W. Allergic rhinitis-induced nasal congestion: its impact on sleep quality. Prim Care Respir J. 2008;17(1):7-18.

Kubavat AH, Pawar P, Mittal R. An open label, active controlled, multicentric clinical trial to assess the efficacy and safety of fluticasone furoate nasal spray in adult Indian patients suffering from allergic rhinitis. J Assoc Physicians India. 2011;59:424-8.

Singh AB, Kumar P. Aeroallergens in clinical practice of allergy in India. An overview. Ann Agric Environ Med. 2003;10(2):131-6.

Singh AB, Shahi S. Aeroallergens in clinical practice of allergy in India- ARIA Asia Pacific Workshop report. Asian Pac J Allergy Immunol. 2008;26(4):245-56.

Shah A, Pawankar R. Allergic rhinitis and co-morbid asthma: perspective from India ARIA Asia- Pacific Workshop report. Asian Pac J Allergy Immunol. 2009;27(1):71-7.

Lagos J.A. Montelukast in the management of allergic rhinitis. Ther Clin Risk Manag. 2007;3:327-32.

Deem K, Ponikau P. Management of allergic rhinitis implementation of evidence-based guidelines. Touch Briefings. 2008.

Mösges R, König V, Köberlein J. The effectiveness of levocetirizine in comparison with loratadine in treatment of allergic rhinitis a meta-analysis. Allergol Int. 2011;60(4):541-6.

Philip G, Malmstrom, K, Hampel FC. Montelukast for treating seasonal allergic rhinitis: a randomized, double blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020-8.

Ciebiada M, Ciebiada MG. Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine. J Investig Allergol Clin Immunol. 2008;18(5):343-9.

Adelsberg VJ, Philip G, Pedinoff AJ. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003;58(12):1268-76.

Goodman M, Jhaveri M, Saverno K. Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms. Am Health Drug Benefits. 2008;1(8):26-34.

Adsule SM, Misra D. Long term treatment with montelukast and levocetirizine combination in persistent allergic rhinitis: review of recent evidence. J Indian Med Assoc. 2010;108(6):381-2.

Ciebiada M, Ciebiada GM, DuBuske LM. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(5):664-71.

Ciebiada M, Ciebiada GM, Barylski M. Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. Am J Rhinol Allergy. 2011;25(1):1-6.

Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial. Indian J Pharmacol. 2016;48(6):649-53.

Kim MK, Lee SY, Park HS, Yoon HJ, Kim SH, Cho YJ, et al. A randomized, multicenter, double-blind, phase III study to evaluate the efficacy on allergic rhinitis and safety of a combination therapy of montelukast and levocetirizine in patients with asthma and allergic rhinitis. Clin Ther. 2018;40(7):1096-107.

Andhale S, Goel HC, Nayak S. Comparison of effect of levocetirizine or montelukast alone and in combination on symptoms of allergic rhinitis. Indian J Chest Dis Allied Sci. 2016;58(2):103-5.

Saverno KR, Seal B, Goodman MJ, Meyer K. Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis. Am Health Drug Benefits. 2009;2(7):309-16.






Original Research Articles